Anticitrullinated antibodies recognize rheumatoid arthritis associated T-cell epitopes modified by bacterial L-asparaginase.
L-asparaginase
T-cell epitopes
anti-citrullinated protein antibodies (ACPAs)
pathogenesis
posttranslational modifications
rheumatoid arthritis
type II collagen
Journal
Central-European journal of immunology
ISSN: 1426-3912
Titre abrégé: Cent Eur J Immunol
Pays: Poland
ID NLM: 9702239
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
03
2023
accepted:
07
07
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
ppublish
Résumé
Citrullinated proteins and anti-citrullinated protein antibodies (ACPAs) play an important role in the pathogenesis of rheumatoid arthritis (RA). It has been suggested that during inflammation or dysbiosis, bacteria could initiate production of ACPAs. Most patients with RA are seropositive for ACPAs, but these antibodies have overlapping reactivity to different posttranslational modifications (PTMs). For initiation and development of RA, T lymphocytes and T cell epitopes are still required. In this study, we evaluated the ability of bacterial L-asparaginase to modify RA-related T cell epitopes within type II collagen (CII259-273 and CII311-325), as well as whether these modified epitopes are recognized by ACPAs from RA patients. We included 12 patients with early RA and 11 healthy subjects selected according to predefined specific criteria. LC-MS/MS analyses revealed that the bacterial L-asparaginase can modify investigated T cell epitopes. ELISA tests showed cross-reactivity of ACPA positive sera from early RA patients towards the enzymatically modified immunodominant T cell epitopes within type II collagen (CII), but not to the modified irrelevant peptides. These data suggest that the cross-reactive ACPAs recognize the "carbonyl-Gly-Pro" motif in CII. Moreover, the T cell recognition of the modified major immunodominant T cell epitope Gal264-CII259-273 was not affected. This epitope was still able to activate autoreactive T cells from early RA patients. It is likely that such modifications are the missing link between the T cell priming and the development of anti-modified protein antibodies (AMPAs). Our results provide additional information on the etiology and pathogenesis of RA.
Identifiants
pubmed: 37901867
doi: 10.5114/ceji.2023.131455
pii: 51466
pmc: PMC10604640
doi:
Types de publication
Journal Article
Langues
eng
Pagination
174-188Informations de copyright
Copyright © 2023 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Front Genet. 2015 Jun 19;6:211
pubmed: 26150826
J Rheumatol. 2000 Dec;27(12):2743-6
pubmed: 11128658
Front Cell Dev Biol. 2020 Sep 29;8:538130
pubmed: 33134291
Nat Rev Rheumatol. 2017 Oct;13(10):606-620
pubmed: 28835673
Immunol Rev. 2020 Mar;294(1):148-163
pubmed: 31845355
Arthritis Rheum. 2010 Jul;62(7):1911-20
pubmed: 20309862
Cells. 2019 Jun 29;8(7):
pubmed: 31261953
Immunobiology. 2022 Jul;227(4):152233
pubmed: 35667151
Genomics Proteomics Bioinformatics. 2018 Aug;16(4):244-251
pubmed: 30244175
Rheumatology (Oxford). 2019 Sep 1;58(9):1623-1633
pubmed: 30892636
Appl Biochem Biotechnol. 2016 Mar;178(5):900-23
pubmed: 26547852
Infect Immun. 2011 Sep;79(9):3476-91
pubmed: 21646455
Cell Chem Biol. 2018 Jun 21;25(6):691-704.e6
pubmed: 29628436
Database (Oxford). 2021 Apr 7;2021:
pubmed: 33826699
Antibodies (Basel). 2017 Mar 08;6(1):
pubmed: 31548521
Expert Rev Mol Diagn. 2021 Jul;21(7):685-702
pubmed: 34024239
Arthritis Rheumatol. 2019 Feb;71(2):210-221
pubmed: 30152126
Arthritis Res Ther. 2014 Jul 08;16(4):R143
pubmed: 25005029
Int J Mol Sci. 2021 Sep 30;22(19):
pubmed: 34638916
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9960-5
pubmed: 12089323
Microorganisms. 2020 Aug 04;8(8):
pubmed: 32759661
Int J Mol Sci. 2021 Jan 12;22(2):
pubmed: 33445768
Cell Mol Life Sci. 2022 Jan 25;79(2):94
pubmed: 35079870
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679953
Curr Opin Immunol. 2012 Feb;24(1):112-8
pubmed: 22209691
Probiotics Antimicrob Proteins. 2022 Feb;14(1):99-113
pubmed: 34036479
J Chromatogr A. 2022 Aug 16;1678:463352
pubmed: 35896048
J Proteomics. 2015 Oct 14;128:352-64
pubmed: 26341301
Postgrad Med. 2023 Apr;135(3):214-223
pubmed: 35275765
Ann Rheum Dis. 2009 May;68(5):736-43
pubmed: 18635594
Arthritis Rheum. 2012 Aug;64(8):2482-8
pubmed: 22392632
Mol Biol Rep. 2022 Mar;49(3):2475-2485
pubmed: 34855107
Front Immunol. 2021 May 14;12:685312
pubmed: 34054878
Antibodies (Basel). 2021 Jul 21;10(3):
pubmed: 34449533
Clin Exp Immunol. 2009 Jan;155(1):1-15
pubmed: 19076824
Mod Rheumatol. 2006;16(5):276-81
pubmed: 17039307
Cancers (Basel). 2022 Feb 11;14(4):
pubmed: 35205650
Pharmaceutics. 2022 Mar 09;14(3):
pubmed: 35335974
FEBS J. 2021 Jul;288(14):4183-4209
pubmed: 34060231
Ann Rheum Dis. 2017 Sep;76(9):1529-1536
pubmed: 28336519
Arthritis Rheum. 2013 Jan;65(1):69-80
pubmed: 23044660
Ann Rheum Dis. 2011 Jan;70(1):188-93
pubmed: 20736390
PLoS One. 2015 Dec 10;10(12):e0144707
pubmed: 26657009
Curr Opin Immunol. 2004 Dec;16(6):753-8
pubmed: 15511669
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arthritis Rheumatol. 2016 May;68(5):1124-35
pubmed: 26713667
Curr Protein Pept Sci. 2021;22(7):548-558
pubmed: 33588725
Best Pract Res Clin Rheumatol. 2019 Dec;33(6):101492
pubmed: 32151461
Eur J Immunol. 2005 Feb;35(2):357-66
pubmed: 15682451
Int J Mol Med. 2015 Sep;36(3):607-26
pubmed: 26178806
Int J Mol Sci. 2020 Jun 04;21(11):
pubmed: 32512739
Int J Biochem Cell Biol. 2006;38(10):1662-77
pubmed: 16730216
Int J Mol Sci. 2022 Aug 15;23(16):
pubmed: 36012429
Ann Rheum Dis. 2019 Jul;78(7):908-916
pubmed: 31151934